Alnylam Pharmaceuticals
ALNY
566 hedge funds and large institutions have $34.1B invested in Alnylam Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 106 funds opening new positions, 222 increasing their positions, 170 reducing their positions, and 57 closing their positions.
86% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 57
31% more repeat investments, than reductions
Existing positions increased: 222 | Existing positions reduced: 170
17% more capital invested
Capital invested by funds: $29.1B → $34.1B (+$4.92B)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more call options, than puts
Call options by funds: $364M | Put options by funds: $325M
9% more funds holding
Funds holding: 521 → 566 (+45)
1.69% more ownership
Funds ownership: 94.78% → 96.47% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$653M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$518M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$400M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$250M |
| 5 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$142M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$327M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$298M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$122M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$97.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$89.4M |
ALNY Hedge Fund Activity: Q3 2024 in Review
566 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2024, worth a combined $34.1B — up 17% from $29.1B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new ALNY positions and 57 closed out — a net gain of 49 holders — while 222 added to existing stakes and 170 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $653M. The largest seller was Wellington Management Group, cutting an estimated $327M.
- 566 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2024, up from 521 in Q2 2024.
- Funds reported $34.1B of Alnylam Pharmaceuticals stock for Q3 2024, up 17% quarter-over-quarter.
- 106 funds opened new Alnylam Pharmaceuticals positions in Q3 2024 and 57 closed out, a net change of +49 holders.
- The largest Alnylam Pharmaceuticals buyer in Q3 2024 was Fidelity Investments, an estimated $653M added.
- The largest Alnylam Pharmaceuticals seller in Q3 2024 was Wellington Management Group, an estimated $327M sold.
Based on aggregated 13F filings for Q3 2024.